News

Focusing on Rare Diseases, CGeneTech Research Develops New Drug Expected to Bring Gospel to Patients with Multiple Sclerosis

  • Categories:Company News
  • Author:admin
  • Origin:
  • Time of issue:2019-02-28
  • Views:0

(Summary description)Today is the 12th International Rare Disease Day. Remember the Ice Bucket Challenge that took the world by storm in 2014 and sparked the attention of the community to rare diseases including acromegaly? Teriflunomide, a new class 3.1 drug developed by CGeneTech, has recently officially launched a clinical trial for consistency evaluation against multiple sclerosis similar to acromegaly, which is expected to bring gospel to domestic multiple sclerosis patients!

Focusing on Rare Diseases, CGeneTech Research Develops New Drug Expected to Bring Gospel to Patients with Multiple Sclerosis

(Summary description)Today is the 12th International Rare Disease Day. Remember the Ice Bucket Challenge that took the world by storm in 2014 and sparked the attention of the community to rare diseases including acromegaly? Teriflunomide, a new class 3.1 drug developed by CGeneTech, has recently officially launched a clinical trial for consistency evaluation against multiple sclerosis similar to acromegaly, which is expected to bring gospel to domestic multiple sclerosis patients!

  • Categories:Company News
  • Author:admin
  • Origin:
  • Time of issue:2019-02-28
  • Views:0

Today is the 12th International Rare Disease Day. Remember the Ice Bucket Challenge that took the world by storm in 2014 and sparked the attention of the community to rare diseases including acromegaly? Teriflunomide, a new class 3.1 drug developed by CGeneTech, has recently officially launched a clinical trial for consistency evaluation against multiple sclerosis similar to acromegaly, which is expected to bring gospel to domestic multiple sclerosis patients!

Multiple sclerosis is the most common type of central nervous demyelinating disease, characterized by speech, vision, motor and sensory impairments and cerebral neuropathies. It was reported in 2013 that scientists at Hopkins found that amyotrophic lateral sclerosis, or what we commonly call acromegaly, may have something in common with multiple sclerosis. Multiple sclerosis researchers may be able to interface with some of the same treatments that slow the progression of amyotrophic lateral sclerosis, thus opening the door to a treatment for acromegaly.

Currently, multiple sclerosis affects more than 350,000 people in the United States, 40-50,000 domestically, and approximately 2.5 million worldwide. Symptoms usually appear in the 20s and 40s, with twice as many women as men suffering from the disease, and most patients are in the relapse phase of the disease. The goal of treating MS is to reduce the duration and worsening of symptoms associated with relapses, prevent the incidence of relapses, and delay the accumulation of the disease.

The development of drugs for the treatment of rare diseases has not been forgotten by society. Many countries around the world, especially some developed countries, have generally established systems to encourage the development of therapeutic drugs for rare diseases.In 2013, the State Drug Administration issued [2013] No. 37, which clearly prioritized the review of innovative and generic drugs for the treatment of rare diseases.


On May 22, 2018, the Health Planning Commission included multiple sclerosis in the rare disease catalog, which accelerated the approval process of related drugs. Therefore, the drug independently developed by Centurion Technology only needs to complete the drug consistency evaluation on healthy human bodies before it can apply for marketing and sales. According to Dr. Qiang Yu, CEO of CGeneTech, the completed clinical pre-experiments have met the standards, and the API and formulation levels are the same as those of the original product, and all experimental content is expected to be completed this year. At present, there is no similar product in China except for the import of Teriflunomide from the original research manufacturer Sanofi. Teriflunomide from CGeneTech will be of the same quality as the foreign original research and at a favorable price to relieve the pain of domestic MS patients.

The

The world's first SGLT-2/DPP-4 dual target inhibitor with complementary advantages has been approved for clinical use

Recently, Shengshi Taike's Class 1 innovative drug SGLT-2/DPP-4 dual target inhibitor CGT-2201 has been granted implicit permission for clinical trials by the National Drug Administration. CGT-2201, which targets SGLT-2 and DPP-4, two important targets related to glucose metabolism, can be better used for the treatment of diabetes and its derivatives, including diabetes nephropathy and non-alcoholic fatty liver disease. In 2021, the number of diabetes patients in China will reach 141 million, ranking first in the world. Among the numerous patients with diabetes in China, 20-40% may suffer from complications of diabetes nephropathy. Among the existing hypoglycemic drugs, only sodium glucose cotransporter 2 (SGLT-2) inhibitor has significant renal protection effect in clinical verification, but its inherent reproductive and urinary system infection risks limit its use. Based on SGLT-2 inhibitors and combined with the characteristics of dipeptidyl peptidase 4 (DPP-4) inhibitors, we design and develop a drug that can improve blood sugar, reduce side effects of urinary and reproductive system infections, is not limited by renal function, and has kidney benefits. It is expected to fill the market gap and meet the needs of patients. Based on this market background and target characteristics, Shengshi Taike utilizes its own small molecule chimera drug technology platform to develop multi head multifunctional new drug products with synergistic mechanisms, with CGT-2201 being one of its representative works. It fuses the respective mechanism characteristics of SGLT-2 and DPP-4. On the basis of inhibiting the activity of SGLT-2 to reduce the reabsorption of glucose in the kidney, it also slows down the inactivation of DPP-4 on GLP-1, playing a dual role mechanism to play a superposition effect; While achieving considerable hypoglycemic effect, it can reduce the side effects of existing SGLT-2 drug urinary system infection; At the same time, without kidney excretion, it can reduce the burden of the kidney and reduce the contraindication of diabetes patients with renal insufficiency. Therefore, this drug will have the advantage of better controlling blood sugar and protecting patient kidney function. Shengshi Tyco was founded in Suzhou Industrial Park in 2010. Its core team has decades of experience in the whole life cycle of international drugs, and is committed to the R&D and industrialization of high-quality and differentiated small molecule innovative drugs. The company has built a product pipeline covering multiple disease fields such as hypoglycemic, anticancer, and autoimmune diseases with an integrated drug research and development technology platform and a diversified business perspective. In the field of hypoglycemic drugs, Shenggliptin, the core product independently developed by the company, has submitted an NDA (product launch application) to the National Drug Administration and has been accepted. The results of the Phase 3 clinical trial showed that low doses can reach the predetermined trial endpoint, while the high-dose group can also demonstrate the safety of the drug well. The therapeutic effect of "half the dose" is twice as effective, making it expected to become the best hypoglycemic drug in the class. At the same time, the company has also carried out a comprehensive layout around oral drugs and derivative diseases of various targets related to diabetes. CGT-2201, which was approved for clinical use this time, is one of its pipeline matrix members.
2023-04-20

Contact Us

Add:Room 101, Bld C11, 218 Xinghu Rd,Suzhou industrial Park,China, 215123

Tel: +86-512-62956960(Recruitment)

         +86-512-62956961(marketing)

Copyright © 2022  CGeneTech (Suzhou, China) Co., Ltd.  All rights reserved.  苏ICP备2022006552号-1  Powered by 300.cn  SEO